about
Helminth parasite proteomics: from experimental models to human infectionsNovel therapeutic and prevention approaches for schistosomiasis: reviewImmunoprotection of mice against Schistosomiasis mansoni using solubilized membrane antigensGenetic knockdown and pharmacological inhibition of parasite multidrug resistance transporters disrupts egg production in Schistosoma mansoniPraziquantel treatment decreases Schistosoma mansoni genetic diversity in experimental infectionsChemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasisAn artemisinin derivative of praziquantel as an orally active antischistosomal agentPraziquantel affects the regulatory myosin light chain of Schistosoma mansoni.Susceptibility to praziquantel of male and female cercariae of praziquantel-resistant and susceptible isolates of Schistosoma mansoni.Modulation of a Schistosoma mansoni multidrug transporter by the antischistosomal drug praziquantel.Non-invasive index of liver fibrosis induced by alcohol, thioacetamide and Schistosomal infection in mice.Design and synthesis of molecular probes for the determination of the target of the anthelmintic drug praziquantel.Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantelMetabolic profiling of praziquantel enantiomers.Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials.Pharmacology and potential physiological significance of schistosome multidrug resistance transportersTetrasubstituted pyrazinones derived from the reaction of praziquantel with N-bromosuccinimide.Voltage-gated calcium channel subunits from platyhelminths: potential role in praziquantel action.Ca2+ signalling, voltage-gated Ca2+ channels and praziquantel in flatworm neuromusculature.Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance.Therapeutic evaluation of sustained-releasing praziquantel (SRP) for clonorchiasis: phase 1 and 2 clinical studiesSchistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibilityNew insight into praziquantel against various developmental stages of schistosomes.Molecular modeling and infrared and Raman spectroscopy of the crystal structure of the chiral antiparasitic drug Praziquantel.Schistosome calcium channel beta subunits. Unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel.Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance.Immune dependence of schistosomicidal chemotherapy: an ultrastructural study of Schistosoma mansoni adult worms exposed to praziquantel and immune serum in vivo.Treatment of Schistosoma mansoni with miltefosine in vitro enhances serological recognition of defined worm surface antigens.Senna leaf extracts induced Ca(+2) homeostasis in a zoonotic tapeworm Hymenolepis diminuta.Metabolite profiling of praziquantel and its analogs during the analysis of in vitro metabolic stability using information-dependent acquisition on a hybrid triple quadrupole linear ion trap mass spectrometer.Pharmacokinetics and microsomal oxidation of praziquantel and its effects on the P450 system in three-month-old lambs infested by Fasciola hepatica.Susceptibility of Schistosoma japonicum to praziquantel in China.Schistosoma mansoni: praziquantel-induced tegumental lesion exposes actin of surface spines and allows binding of actin depolymerizing factor, gelsolin.Chemotherapy-induced, age-related changes in antischistosome antibody responses.Antischistosomal activity of ginger (Zingiber officinale) against Schistosoma mansoni harbored in C57 mice.Molecular characterization of voltage-gated calcium channel β-subunits of Clonorchis sinensis.Pharmacological and immunological effects of praziquantel against Schistosoma japonicum: a scoping review of experimental studies.Changes in specific anti-egg antibody levels following treatment with praziquantel for Schistosoma haematobium infection in children.Schistosoma mansoni: stage-dependent damage after in vivo treatment with praziquantel.Schistosoma mansoni: larval damage and role of effector cell(s) in the synergy between vaccine immunity and praziquantel treatment.
P2860
Q26863301-5DB84D68-F05E-48B5-A1A3-DD97737FB411Q27008897-C5F4264E-C02F-4564-B5CD-7816ED90CE59Q27305172-F1C992A9-FE4E-4737-A099-B1619FF548F0Q28478288-09A17AF5-8B47-43E3-943A-9956A479A980Q28537753-5646A592-28D6-46A8-8A86-7A39D59DAC6DQ28539314-B37B87F3-AF37-4557-938F-26847F255411Q28544852-97464AFF-B46A-4DE2-92C4-6B17EC2A4300Q33395216-C86F37C1-DEAE-401F-97C3-D8D37369395BQ33504927-56F8BE5E-4533-43F1-BCB1-3846C71F29F0Q33552868-20D0652C-B715-41EE-8137-01FCB7C2190FQ33591803-246F23D2-BDAF-4510-963A-09DCE7B161D9Q33747366-0A86CC38-CB91-4284-9FFC-FD0EE02A3E85Q33960332-8EFF5DF4-C00F-4578-AFCC-865E3D3843CFQ34208792-27FD6789-43FE-46AB-A1D4-376220F5BC81Q34939414-CFD154FB-7727-4625-9700-A90D647B015BQ35159499-2F3E88CC-5E47-448B-8748-371451D6DC33Q35225427-7159C75C-EE59-4A1A-9933-1C5EA23C1002Q36424568-C4B4E5FD-AC08-494F-BB9A-0CBCB4D5A4A4Q36434081-F95B19C6-B9ED-4AC6-A267-F45B7B035304Q36441487-2DE73425-4098-4088-B7E5-999E269C419AQ36919402-B32E820F-9C3D-41FF-ACAE-356937A05E29Q37223703-6E76D6DA-962C-4E30-9D58-ECAD32BCDE18Q37943763-D615F52E-C2B4-42F1-BD89-CB3DBF64B8B1Q38919284-B58E640A-1A2E-4DAB-9D42-AE084A087E29Q39143568-305F3D3F-8D06-43A3-A6E1-FB9683CA7345Q39164325-88277C99-3D4A-493A-A5EB-F76B8C879D20Q39257435-E2DBE9CE-B1DF-44F4-8FEC-E5C2FA521DFEQ40079529-E0591A55-7478-426F-A459-F6D78AA4A0A4Q40791018-8BBD9EB8-3420-460D-8A0E-3C382247F921Q42874589-BD38FC6F-17A2-4A3A-A07A-239B8EC4B214Q43736160-CAF0F037-D7EC-4698-BC27-FBA36339C66CQ43736333-77281411-69D5-4811-AB8C-47A254DC4FEEQ43768518-4D6FFBB7-2FAD-423A-A272-8CC9A2A4FFC1Q44468424-B9A28EE9-AC3C-4114-8DF5-D04230ACE716Q45721251-FD5A372A-6697-4A1F-A5EE-55520DD63487Q46760732-355BCEA8-BD24-400E-98CC-4DBA8DA47ED0Q49632990-367A35DC-2690-4252-8BC3-E855FFCC09F2Q50532513-33763DE0-BCE5-410B-A3BA-028DF76A7BF0Q52242503-A8E08395-F68F-4E74-A883-6EB083E7B240Q52480007-4B4B1CEF-95B8-4211-A0F6-3BCB91DB0951
P2860
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh
1985年學術文章
@zh-hant
name
Praziquantel: mechanisms of anti-schistosomal activity.
@en
Praziquantel: mechanisms of anti-schistosomal activity.
@nl
type
label
Praziquantel: mechanisms of anti-schistosomal activity.
@en
Praziquantel: mechanisms of anti-schistosomal activity.
@nl
prefLabel
Praziquantel: mechanisms of anti-schistosomal activity.
@en
Praziquantel: mechanisms of anti-schistosomal activity.
@nl
P1476
Praziquantel: mechanisms of anti-schistosomal activity.
@en
P2093
P304
P356
10.1016/0163-7258(85)90020-8
P577
1985-01-01T00:00:00Z